Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled trial of icatibant in acute hereditary angioedema attacks
2009-015606-19Phase 3Completed
- Sponsor
- Jerini AG
- Start
- Nov 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hereditary angioedema (HAE) comparing Icatibant with Placebo (2 arms). Primary endpoint: Time to symptom relief for the first attack. Started Nov 2009; status: completed.
02
Drugs
icatibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2009-015606-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015606-19.